135 related articles for article (PubMed ID: 2560399)
1. Recombinant human müllerian inhibiting substance inhibits epidermal growth factor receptor tyrosine kinase.
Cigarroa FG; Coughlin JP; Donahoe PK; White MF; Uitvlugt N; MacLaughlin DT
Growth Factors; 1989; 1(2):179-91. PubMed ID: 2560399
[TBL] [Abstract][Full Text] [Related]
2. Müllerian inhibiting substance blocks autophosphorylation of the EGF receptor by inhibiting tyrosine kinase.
Coughlin JP; Donahoe PK; Budzik GP; MacLaughlin DT
Mol Cell Endocrinol; 1987 Jan; 49(1):75-86. PubMed ID: 3030847
[TBL] [Abstract][Full Text] [Related]
3. Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive.
Maggard MA; Catlin EA; Hudson PL; Donahoe PK; MacLaughlin DT
Metabolism; 1996 Feb; 45(2):190-5. PubMed ID: 8596488
[TBL] [Abstract][Full Text] [Related]
4. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
[TBL] [Abstract][Full Text] [Related]
5. Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro.
Ueno S; Manganaro TF; Donahoe PK
Endocrinology; 1988 Sep; 123(3):1652-9. PubMed ID: 2456917
[TBL] [Abstract][Full Text] [Related]
6. Human recombinant mullerian inhibiting substance inhibits epidermal growth factor.
Coughlin JP; Cigarroa F; Donahoe PK; McLaughlin DT
Curr Surg; 1988; 45(3):204-5. PubMed ID: 3402255
[No Abstract] [Full Text] [Related]
7. Müllerian inhibiting substance in reproduction and cancer.
Donahoe PK
Mol Reprod Dev; 1992 Jun; 32(2):168-72. PubMed ID: 1637555
[TBL] [Abstract][Full Text] [Related]
8. Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat.
Tsuji M; Shima H; Yonemura CY; Brody J; Donahoe PK; Cunha GR
Endocrinology; 1992 Sep; 131(3):1481-8. PubMed ID: 1505479
[TBL] [Abstract][Full Text] [Related]
9. Insensitivity of the chick embryo müllerian duct to human recombinant müllerian-inhibiting substance.
Weniger JP; Cate RL; Zeis A
J Mol Endocrinol; 1992 Feb; 8(1):73-7. PubMed ID: 1543536
[TBL] [Abstract][Full Text] [Related]
10. Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level.
Teixeira J; Fynn-Thompson E; Payne AH; Donahoe PK
Endocrinology; 1999 Oct; 140(10):4732-8. PubMed ID: 10499532
[TBL] [Abstract][Full Text] [Related]
11. Identification of müllerian inhibiting substance specific binding in human cell lines.
MacLaughlin DT; Levin RK; Catlin EA; Taylor LA; Preffer FI; Donahoe PK
Horm Metab Res; 1992 Dec; 24(12):570-5. PubMed ID: 1478615
[TBL] [Abstract][Full Text] [Related]
12. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK
Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990
[TBL] [Abstract][Full Text] [Related]
13. Mullerian inhibiting substance binding and uptake.
Catlin EA; Ezzell RM; Donahoe PK; Manganaro TF; Ebb RG; MacLaughlin DT
Dev Dyn; 1992 Apr; 193(4):295-9. PubMed ID: 1511169
[TBL] [Abstract][Full Text] [Related]
14. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
15. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.
Kim JH; Seibel MM; MacLaughlin DT; Donahoe PK; Ransil BJ; Hametz PA; Richards CJ
J Clin Endocrinol Metab; 1992 Sep; 75(3):911-7. PubMed ID: 1517385
[TBL] [Abstract][Full Text] [Related]
17. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Segev DL; Hoshiya Y; Hoshiya M; Tran TT; Carey JL; Stephen AE; MacLaughlin DT; Donahoe PK; Maheswaran S
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):239-44. PubMed ID: 11773638
[TBL] [Abstract][Full Text] [Related]
18. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
19. The müllerian inhibitor and mammalian sexual development.
Behringer RR
Philos Trans R Soc Lond B Biol Sci; 1995 Nov; 350(1333):285-8; discussion 289. PubMed ID: 8570693
[TBL] [Abstract][Full Text] [Related]
20. A possible purification of mullerian inhibiting substance and a model for its mechanism of action.
Budzik GP; Donahoe PK; Hutson JM
Prog Clin Biol Res; 1985; 171():207-23. PubMed ID: 2984697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
